Keating - Copyright Lippincott Williams &...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Copyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Mesenchymal stromal cells Armand Keating Purpose of review Our understanding of the biology and properties of mesenchymal stem cells or multipotent mesenchymal stromal cells has expanded dramatically over the last 3 years and is likely to have an impact on clinical practice in the near future, making a review of this topic both timely and relevant Recent findings Recommendations regarding nomenclature and the definition of mesenchymal stromal cells have been proposed, a rapidly dividing population within the mesenchymal stromal cell compartment has been better defined and the ability of these cells to exhibit characteristics of cells from a variety of lineages has been extended. The notion that tissue repair with mesenchymal stromal cells is related to transdifferentiation has been re-evaluated and, for the myocardium at least, may be due rather to a paracrine mechanism. The most dramatic developments have been in identifying some of the complex mechanisms underlying the immunosuppressive and nonimmunogenic properties of mesenchymal stromal cells which have important implications for the management of conditions like acute graft-versus-host disease. Summary Mesenchymal stromal cells are a biologically important cell population that are able to support hematopoiesis, can differentiate along mesenchymal and nonmesenchymal lineages in vitro , are capable of suppressing alloresponses and appear to be nonimmunogenic. These properties suggest emerging roles for mesenchymal stromal cells in cell therapy. Keywords graft-versus-host disease, immune suppression, marrow stromal cells, mesenchymal stem cells, nonimmunogenicity Curr Opin Hematol 13:419425. 2006 Lippincott Williams & Wilkins. Princess Margaret Hospital/Ontario Cancer Institute, Faculty of Medicine and Institute for Biomaterials and Biomedical Engineering, University of Toronto, Canada Correspondence to Armand Keating MD, Princess Margaret Hospital/Ontario Cancer Institute, 610 University Avenue, Toronto, ON, Canada M5G 2M9, Tel: +1 416 946 4595; fax: +1 416 946 4530; e-mail: armand.keating@uhn.on.ca Current Opinion in Hematology 2006, 13:419425 Abbreviations GVHD graft-versus-host disease IDO indoleamine 2,3-dioxygenase IFN interferon IL interleukin MLC mixed lymphocyte culture MSC mesenchymal stromal cell PVR polivirus receptor 2006 Lippincott Williams & Wilkins 1065-6251 Introduction The population of cells variously known as mesenchymal stem cells, marrow stromal cells and more recently, mesenchymal stromal cells, all designated by the acronym MSC, has been the subject of intensive inves- tigation over the past decade. These cells, previously recognized as critical to the support of hematopoiesis [1], can differentiate in vitro along mesenchymal (adipocytic, osteoblastic and chondrocytic) lineages [2] and to varying degrees can be made to exhibit neuronal [3], hepatic [4] and cardiac [5] characteristics, suggesting a possible role...
View Full Document

This note was uploaded on 02/14/2011 for the course ORGANIC CH 341 taught by Professor Idk during the Spring '11 term at Wisconsin.

Page1 / 7

Keating - Copyright Lippincott Williams &...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online